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Whilst the literature supports that drug addicts who engage in polysubstance use are 
more likely to experience poorer treatment outcomes and psychological distress, there is also 
some evidence that hallucinogens can treat addiction and psychological distress (Tupper et 
al., 2015). The aim of this research was to investigate whether individuals who are addicted 
to methamphetamine and consume hallucinogens achieve poorer treatment outcomes than 
individuals who are addicted to methamphetamine and abstain from hallucinogens. It was 
hypothesised that the individuals who engaged in hallucinogen use would experience greater 
levels of physical, psychological and social harm than those who abstained from 
hallucinogens. The sample included 1159 methamphetamine-addicted outpatients from 
Psychmed’s Matrix program and the data was obtained through Psychmed’s electronic 
database. Outpatients were coded into a “non-hallucinogen” group and a “hallucinogen” 
group. A repeated measures ANOVA compared outpatients’ wellbeing and addiction scores 
obtained prior to treatment and post treatment.  Although both the non-hallucinogen group 
and the hallucinogen group experienced an improvement in scores post treatment, the 
hallucinogen group consistently had greater levels of harm at baseline and upon completion 
of the program. This suggests that hallucinogen use is correlated with poorer treatment 
outcomes. As a result, outpatient rehabilitation programs need to encourage abstinence from 
all substances during treatment. This research will give outpatient drug rehabilitation 
programs the evidence to shift their focus onto addressing secondary substance use and how 
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Chapter 1. Introduction 
1.1 Significance & Background 
         Methamphetamine (Meth) is a highly potent and addictive synthetic illicit 
substance. It is classified as a phenylethylamine psychostimulant and operates on the central 
nervous system (Pey et al., 2016).  Meth’s chemical structure is highly similar to 
amphetamine’s structure, but it contains an added N-methyl group which increases lipid 
solubility and promotes a more rapid crossing of the blood–brain barrier. As a result, the 
onset of meth’s effects are much quicker and more intense than other stimulants such as 
amphetamine and cocaine (Black et al., 2017). Meth is primarily produced in either a powder 
form which the user either snorts or injects, or in a crystallised form that can be smoked or 
injected (Budman et al., 2009). When ingested, meth forces neurons in the mesolimbic 
pathway of the brain to rapidly release stored monoamine neurotransmitters. It also inhibits 
reuptake of these substances back into the axon terminal, leading to high concentrations in 
neuronal synapses (Ferrucci et al., 2019). Although numerous different monoamine 
neurotransmitters are released, dopamine, norepinephrine and serotonin have the most 
significant effects on the individual (Black et al., 2017).  
           Dopamine regulates feelings of pleasure, with controlled amounts being 
released during enjoyable experiences such as eating, shopping, and sexual experiences. The 
high concentrations of dopamine produces intense euphoria, increased confidence, alertness, 
and a heightened sense of wellbeing (Berridge & Kringelbach, 2015; Lin et al., 2016). 
However, excess dopamine also disrupts the sleep cycle and promotes alertness and 
wakefulness, sometimes causing individuals who have ingested meth to stay awake for days 
at a time (Hedges et al., 2018; Radfar & Rawson, 2014). Serotonin’s main functions are to 






focus, enabling users to be more productive and efficiently complete tasks, excessive 
amounts can suppress appetite and cause one to feel satisfied despite having an empty 
stomach. Consequently, individuals addicted to meth often experience excessive weight loss 
and malnourishment (Jaehne et al., 2017). Norepinephrine is released during stressful and 
dangerous situations, increasing ones arousal and alertness, acting as a protective mechanism 
for survival. However, excessive amounts of norepinephrine can lead to restlessness and 
anxiety as well as an increased heart rate, blood pressure, and body temperature. When 
overdosing on meth, these effects can lead to arrythmias, hyperpyrexia, hypertension, kidney 
failure, seizures, stroke, haemorrhages, coma and ultimately, death (Degenhardt et al., 2017). 
The positive effects of these neurotransmitters act as a reward for engaging in the experience, 
motivating them to repeatedly engage in the experience. As a result, the behaviour is 
repeatedly reinforced and could potentially lead to addiction (Godino et al., 2015). Long-term 
use can lead to dopamine and serotonin neuron damage which may cause: paranoia, increased 
aggression, depression, hallucinations, and psychosis (Kish et al., 2017). 
          Due to its addictive nature, meth users experience intense withdrawal which can 
significantly affect day-to-day functioning. This is because repeated use of meth disrupts the 
maintenance and depletes the levels of dopamine in the brain. As a result, intense cravings 
are experienced to compensate for the lack of dopamine and this commonly results in 
withdrawal symptoms (Courtney & Ray, 2014). There are two stages of meth withdrawal. An 
acute phase lasts 7-10 days and is symptomatic of excessive sleeping, eating and feelings of 
depression. The second, or sub-acute phase, persists for at least two weeks in which 
symptoms such as poor concentration and memory, fatigue, paranoia, irritability and agitation 
are experienced by the individual (McGregor et al., 2005). Meth cravings can continue for 
approximately five weeks, but the first two weeks are particularly vulnerable for relapse 







1.2 Prevalence of Meth addiction and public health issues 
          Regular meth use in Australia has been steadily declining over the last two 
decades. In 2001, 3.4% of Australians aged 14 years old and over had used meth in the 
previous 12 months, decreasing to 1.3% in 2019 (Australian Institute of Health and Welfare, 
2021). Although less Australians are consuming meth in comparison to the previous two 
decades, meth’s burden on the community, public health, and the individual is increasing in 
severity. In particular, the use of methamphetamine hydrochloride, a purer and more potent 
crystallised form of meth has increased in usage between 2007- 2019 from 27% to 50% of 
Australian users respectively (Australian Institute of Health and Welfare, 2021). The 
increasing use of methamphetamine hydrochloride means that users are more vulnerable to 
experiencing adverse effects and overdose resulting on an increase burden on the health care 
system. According to information drawn from the National Hospital Morbidity Database, 
meth accounted for 4.5% of drug related hospital discharges in 2014-15, which increased to 
8.6% of all drug related hospital discharges in 2018-19 (Australian Institute of Health and 
Welfare, 2021). The National Drug and Alcohol Research Centre revealed that there was an 
increase from 107 meth related deaths in 2011 to 478 meth related deaths in 2019 
(Chrzanowska et al., 2021). As a result, the Australian Institute of Health and Welfare 
declared methamphetamine as Australia’s main drug of concern in 2017 (Australian Institute 
of Health and Welfare, 2017). Moreover, whilst under the influence of meth, individuals are 
more susceptible to act impulsively and undertake acts of crime, violence and aggression 
(McKetin et al., 2014). The estimated social cost of health, crime and road accidents relating 
to meth use was $3.73b.  AUD in 2007 and this increased to $5.024b. AUD in 2014 (Tait et 
al., 2018). This highlights the strong correlation between meth hydrochloride use and 







1.3 Correlates of meth addiction 
             There are many demographic characteristics that are correlated with meth use. 
In Australia, being male increases the likelihood of using meth. In 2019, 7% of Australia’s 
male population and 5% of Australia’s female population had used meth in their lifetime, 
while 2% of males and 0.8% of females had used meth in the previous 12 months (Australian 
Institute of Health and Welfare, 2021). However, males are more likely to seek treatment for 
their addiction than females. Between 2019 and 2020, 34,307 clients across Australia 
received treatment for meth, with approximately two-thirds (66%) of the clients being male. 
3.1% of Aboriginal and Torres Strait Islander Australians have reportedly used meth in the 
previous 12 months, which is 2.2 times more likely than non-Indigenous Australians. Of the 
34,307 clients that received treatment between 2019 and 2020, only 1 in 6 (18%) of clients 
were Indigenous or Torres Strait Islanders (Australian Institute of Health and Welfare, 
2021b). These figures indicate that there are many Aboriginal Australians who are unlikely to 
have meth addictions that are going untreated. Other demographic risk factors include 
identifying as a homosexual or bisexual male. For individuals aged 14 years or older, the 
greatest number of recent methamphetamine use was found amongst men who identified as 
homosexual or bisexual, with 7.1% of this population confirming recent meth use (Australian 
Institute of Health and Welfare, 2021). Younger Australians aged in their 20s and 30s are at a 
significantly greater risk of using methamphetamine. In a sample of 34,307 meth users, 69% 
of males and 72% of females were aged between 20 and 39 years of age (Australian Institute 
of Health and Welfare, 2021b). Degenhardt et al. (2016) found that Australians aged between 
25 and 34 years of age experienced the highest rates of meth use, with 1.50% of this cohort 








1.4 Comorbidities of Meth addiction 
           Meth users often possess multiple psychological, physical, and/or social 
comorbidities that exacerbate meth’s negative effects. Poor mental health and high 
psychological distress have consistently been associated with meth use, with anxiety being 
one of the most common comorbidities in individuals who use meth (Darke et al., 2008; 
Zweben et al., 2004). In Australia, approximately 40% of meth users who attend treatment 
reported having a history of anxiety disorders (McKetan et al., 2008). Hall et al. (1996) also 
found that 76% of 301 regular meth users experienced severe anxiety and 33% experienced 
panic attacks after the onset of meth use. Of this sample, 48% reported having severe anxiety 
prior to meth use, and 11% experienced panic attacks (Hall et al., 1996). Furthermore, 
Conway et al. (2006) reported that 39% of meth users reported a lifetime prevalence of 
anxiety disorders, while Shoptaw et al. (2003) reported a lifetime prevalence of anxiety for 
25% of meth users (Conway et al., 2006; Shoptaw et al., 2003). Hang Su et al. (2017) found 
that in a sample of 210 meth dependant individuals, 34% reported their anxiety symptoms as 
being high, in comparison to just 4% of the general population (Hang Su et al., 2017). 
Anxiety is also a prominent symptom during the first several weeks of meth withdrawal, 
which contributes to the likelihood of experiencing relapse (McGregor et al., 2005; Zorick et 
al., 2010). It is evident that many meth users already had anxiety prior to using 
methamphetamine; however, meth’s use worsens these symptoms.  
Depression is also often correlated with meth use. A cross sectional survey of 500 
individuals who are seeking treatment for meth addiction in Brisbane and Sydney revealed 
that 40% of the sample had identified that they had suffered major depression at some point 
in the previous year (McKetan et al., 2011). Furthermore, a study of 526 meth users found 






meth 30 days prior to receiving treatment, and that more frequent users had higher Beck 
Depression Index scores (M = 13.7. SD = 9.5) than those who abstained (M = 7.7, SD = 8.1) 
(Glassner-Edwards et al., 2009). Finally, there is a significant increase in the probability of 
the individual having a history of physical and/or sexual abuse, mental health illness and 
suicidal ideation in those who engage in polysubstance use (Christian et al., 2007). 
           There are several environmental factors that are correlated with meth use. 
Being unemployed puts individuals at a higher risk of abusing meth. The National Drug 
Strategy Household Survey of 2016 found that in the previous 12 months, unemployed 
individuals were 3.1 times more likely (4.6%) to use meth than employed individuals (1.5%) 
(National Drug Strategy Household Survey, 2016). The literature also supports this, with a 
sample of 1238 meth users from the National Survey of Drug Use and Health reporting that 
91% of the sample were unemployed (Swanke and Flowers, 2013). Additionally, level of 
education has also been associated with meth use, with one study finding that fewer years of 
schooling (OR = 0.8) and homelessness (OR = 2.5) in the previous months were significant 
predictors of meth use (Rognli et al., 2014). Between 2015 and 2018, there was a 22% 
increase in individuals who have obtained a high school diploma or less, and those who had 
received government assistance experienced a 26.2% increase (Palamar et al., 2020). When 
comparing meth users to non-users, non-meth users had completed more years of education 
than individuals who use meth (WMD =2.45 to 2.80) (Yen & Chong, 2006). An additional 
study demonstrated that non meth users were 1.3 times more likely to have studied at higher 
levels of education (Sattah et al., 2002). Lower levels of education and current unemployment 
is associated with ongoing meth use.  
            Polysubstance use is common among meth users (Australian Institute of 
Health and Welfare, 2017; Connor et al., 2014).  Alcohol and cannabis are prevalent among 






(Australian Institute of Health and Welfare, 2017). Furthermore, other common secondary 
substances include benzodiazepines and heroin. These four substances are considered central 
nervous system depressants which are commonly used during the ‘comedown’ period after 
meth ingestion (Quinn et al., 2020; Herbeck et al., 2013).  These substances reportedly assist 
with moderating the effects of withdrawal including: anxiety levels, sleep difficulties and 
pain (Hall et al., 2013). Polysubstance use has negative effects on meth recovery and the 
overall wellbeing of the individual. Hindering abstinence from the primary drug, 
polysubstance use has universally been associated with poorer treatment engagement and 
outcomes. Relapse and dropout rates are higher in those who engage in polysubstance use, 
with an odds ratio of 2.51 for polysubstance users and 1.39 for non-polysubstance users 
(Andersson et al., 2021). Abstaining from secondary substance use is strongly associated with 
decreased frequency of engaging with the primary drug (Wang et al., 2017). Secondary drugs 
cannabis and benzodiazepines have been associated with major depression (OR= 2.3, OR= 
2.1 respectively). Additionally, 42% of those who engaged in cannabis and/or benzodiazepine 
use in the previous month experienced major depression compared to 26% who abstained 
from polysubstance use (McKetin et al., 2011). Polysubstance use has also been associated 
with increased levels of anxiety during meth withdrawal (OR= 3.86) (Su et al., 2017). A 
longitudinal study from 2005-2015 confirmed that polysubstance use was associated with 
anxiety and depression (Burdzovic et al., 2015). Moreover, drug induced psychosis has been 
associated with meth users who engage in polysubstance use, in particular frequent alcohol 
and cannabis use (Arunogiri et al., 2018). Overall, polysubstance use has been associated 
with poorer recovery outcomes.  
          Amongst potential poly-use substances, hallucinogens are a class of drug that 
can produce an altered state of consciousness by inducing hallucinations and distorting ones’ 






hallucinogens by meth users include Lysergic Acid Diethylamide (LSD), Psilocybin 
mushrooms, commonly referred to as “magic” mushrooms, and 3,4-
Methylenedioxymethamphetamine (MDMA). Although it is an amphetamine and has 
stimulant properties, MDMA produces hallucinogenic effects and can be classed as an 
hallucinogen (Meyer, 2013). Emerging evidence in recent years has suggested therapeutic 
benefits of LSD, psilocybin mushrooms and MDMA in treating addiction, depression, 
anxiety and post-traumatic stress disorder (Garcia-Romeu et al., 2016; Tupper et al., 2015). 
This evidence contradicts the literature surrounding polysubstance use and meth addiction 
which indicates poorer treatment outcomes for individuals engaging in multiple drug use 
(Andersson et al., 2021). Evidently, the type of drug consumed by the individual may impact 
the success of the treatment outcome. As this field is relatively new, it is hard to obtain exact 
figures relating to the proportion of meth users that engage in hallucinogen use.  
1.5 Treatment Strategies 
          Within Australia, primary, secondary and tertiary strategies are utilised within 
the community to prevent or treat drug and alcohol addiction. Primary intervention involves 
public health initiatives which attempt to prevent youth from engaging in substance use 
(Coomber et al., 2013). Programs such as the ‘Life Education’ Van visits schools across 
Australia and educate youth on the risks associated with substance use, encouraging them to 
make safer choices (Life Education, 2021). Secondary intervention aims to encourage a 
reduction and safer use for those already engaging in substance use (Coomber et al., 2013). 
For example, needle and syringe programs provide clean and sterilised needles and sharps 
containers to ensure safe disposal of used needles in the community (Carruthers, 2018). 
Tertiary interventions refers to the active treatment of substance abuse with the eventual goal 
of achieving abstinence (Coomber et al., 2013). Hospital detox programs provide medical 






used to counter meth withdrawal symptoms are utilised to help reduce cravings and promote 
abstinence (Karila et al., 2010). Residential programs are long term rehabilitation services 
from 4-6 months in duration which support the individual to recover from their addiction 
whilst living in a safe, drug and alcohol free environment. For example, the ‘Woolshed’ is a 
program in South Australia that not only assists with recovery, but aims to improve the 
individual’s lifestyle, overall health and wellbeing as well as social and work skills. Group 
and individual counselling sessions are conducted as well as stress management classes (Drug 
and Alcohol Services Australia, 2020).  
In addition, there are outpatient programs assist with overcoming addiction whilst the 
individual continues to live and work in their own environment. Outpatient programs are the 
most commonly utilised addiction treatment in Australia, with education and counselling 
being the primary treatment strategies (McKetin et al., 2013b). The Matrix program, to be 
discussed presently, is an example of an successful outpatients program, and utilises trained 
psychologists, lived experience mentors and community engagement to assist with recovery. 
Relapse prevention classes are also applied to the programs (Black et al., 2017). Addiction 
services within Australia are utilised on a primary, secondary and tertiary strategy basis, with 
community outpatient services the most common modality of receiving meth addiction 
treatment.  
           Individuals recovering from meth addiction have found long term abstinence 
challenging. Brecht and Herbeck (2014) found that after one year of receiving outpatient 
treatment, 61% of users relapsed whilst two to five years later, a further 25% had also 
relapsed. It is evident that barriers to meth addiction recovery are prevalent within the 
community, with continued polysubstance use potentially hindering ongoing abstinence 
(Brecht & Herbeck, 2014). However, there is a lack of research on how polysubstance use, 






1.6 The Matrix Program 
          Between 2005 and 2015, clinicians from the South Australian non-government 
organisation Psychmed, noticed a significant increase in the number of people with meth use 
comorbidities. As a response to Australia’s meth epidemic, in 2016, Psychmed implemented 
a pilot trial of a drug rehabilitation program in Adelaide. Named the Matrix program, the 
rehabilitation program was first designed and implemented in 1986 by the Matrix Institute of 
Addictions in Los Angeles, the United States of America in response to the countries growing 
cocaine epidemic (Rawson, 1986). Within the first year of its operation, follow-up data 
demonstrated that clients used significantly less cocaine than when first admitted into the 
program (Rawson et al., 1986). In both 1991 and 1996, replications of this study produced 
similar outcomes, demonstrating the efficacy of the Matrix program (Rawson et al., 1991; 
1995). When implemented in Adelaide, the Matrix program was modified, with its focus 
being shifted from cocaine addiction to meth addiction. It also included Australian language 
and statistics, lived experience mentors, and was extended from a 16-week program to a 20- 
week program.  
           The matrix program supports voluntary individuals who are willing and ready 
to undergo rehabilitation. The aim of the program is to encourage and help support 
individuals with substance addiction to achieve abstinence from their preferred substance and 
increase longevity in remaining in the treatment program. A further goal is to provide 
education to the clients on addiction, relapse and withdrawal symptoms (Black et al., 2017). 
Through receiving support from an accredited therapist, the program also values personal 
accountability and commitment. Weekly urine tests are utilised as a strategy to maintain this 
accountability. For the first five weeks of the program, the outpatient is required to attend two 
early recovery skills sessions per week. Additionally, relapse prevention sessions are offered 






family education sessions and gender group sessions are provided. Six weeks into the Matrix 
program, outpatients begin receiving social support sessions once a week, with this 
continuing for the next 118 weeks. 
           Trained Psychmed psychologists conduct all the sessions, which are also co-
facilitated by a lived experience mentor. The therapeutic approaches that are utilised by 
psychologists include Motivational Interviewing and Cognitive Behavioural Therapy. Three 
individual sessions are also offered which allow outpatients to experience community 
engagement, such as having access to haircuts and makeovers, movie passes, gym attendance 
and relaxation training. The Matrix program has also been effective in Australia. Whilst the 
average remission rate across Australian drug and alcohol rehabilitation programs is only 20 
to 30 percent, the remission rate for the six Adelaide-based Matrix programs averages 
between 55 and 70 percent (Black et al., 2017).  
           Whilst the primary aim of the Matrix program in Adelaide is to assist 
individuals in personal recovery from their meth addiction, the program also collects 
extensive data with the individuals consent to assist with government research. As part of its 
aims to achieve ongoing improvements, the Matrix Program is endeavouring to build a 
stronger evidence, both in relation to the targeting of its service to particular at-risk 
populations, but also to evaluate its outcomes (Black et al., 2017). The research presented in 
this thesis will examine other presenting comorbidities that may be a detriment to meth 
recovery; namely, polysubstance use and examine whether improvements in outcomes across 
the duration of the program differ depending upon the presence of polysubstance use. 
1.7 Aims & Hypothesis 
          The aim of this research was to investigate whether hallucinogen use is related 
to higher or lower levels of psychological, physical and social harm in individuals who are 






that outpatients who engaged in hallucinogen use will experience greater levels of harm at 
program intake and upon completion, than those who are addicted to meth and abstain from 
hallucinogen use. The study also examined whether the presence of poly-substance use 
(hallucinogens) was associated with poorer outcomes as based upon a comparison of 
psychological outcome measures recorded at the baseline assessment in the program and at 
program treatment. The study also explored whether there were age and gender differences in 
























Chapter 2. Method 
2.1 Participants 
The sample was gathered from Psychmed’s Matrix program data which has recorded 
every outpatient who has ever attempted or completed the Matrix program at the South, City 
and North Psychmed locations from 2016 to the present day. Adults over 18 years of age are 
eligible to participate in the Matrix program, with some exceptions being made for a limited 
number of 16 and 17-year olds. Outpatients are required to have been abstinent from meth for 
two weeks prior to commencing the program. Outpatients may choose to attend the Matrix 
program, or are referred by a medical professional. If outpatients continued their meth use 
throughout the first two to four weeks of the program or had relapsed during the program, 
they are encouraged to attend an inpatient detox prior to recommencing the program (Black et 
al., 2017) 
The sample comprised 1159 outpatients that had participated in the Psychmed’s 
Matrix program sometime between 2016 to present day. Table 2.1 summarises the 
demographic characteristics of the sample. As indicated, 62.4% were male and 37.6% were 
female. A total of 39 (3.4%) of the sample identified as Aboriginal or Torres Straight Islander 
(ATSI), while the remaining 96.6% identified as Caucasian or other. Participant age ranged 
from 16 years of age to 67 years of age, with around 70% aged between 25 and 45 years. 
Fewer participants were older or very young. All outpatients were considered “severely 
addicted” to meth, as indicated by the ASSIST questionnaire. Stratified sampling was used to 
categorise outpatients into subgroups based on their type of hallucinogen use. Table 2.1 
shows that 789 (68.1%) of the sample fell into the meth only group, a meth and LSD group 
comprised of 209 (18%) outpatients were categorised into a meth and LSD group, 28 (2.4%) 






and psilocybin users, and finally, 28 (2.4%) individuals indicated that they were meth and 
MDMA users.  
Table 2.1 
Demographics characteristics of the sample (n =  1159) 
___________________________________________________________________________ 
 N (%) 
Gender  
Male 723 (62.4) 
Female 436 (37.6) 
  
Aboriginal/Torres Strait Islander  
Yes 39 (6.6) 
No 1120 (93.4) 
  
Age  
16-25 90 (7.8) 
25-35 409 (35.3) 
35-45 425 (36.7) 
45-67 194 (16.7) 
  
Polyuse  
None 789 (23.1) 
LSD  209 (18.0) 
Psilocybin 28 (2.4) 
LSD & Psilocybin 105 (9.1) 




Several different questionnaires were utilised pre and post treatment to assess 
outpatients’ severity of physical, psychological, and social harm.  
(a)The Opiate Treatment Index (OTI) for methamphetamine examines the severity of 
recent drug use, by asking the user five questions relating to when their three most recent 
days of drug use occurred, and the quantity that they used on their previous two occasions. 






the most recent day of drug use and the time before that are added with the interval between 
the second and third last days of drug use. Then, the total amount consumed is divided by the 
total of the two intervals between use, providing an average amount consumed per day. A 
score of 0.00 indicates abstinence, 0.01 to 0.13 indicates once a week or less, more than once 
a week is 0.14 to 0.99, daily use is between 1.00 and 1.99, and more than once a day is 2.00 
or more. The OTI for social functioning assesses social integration in the previous six months 
by asking the user twelve questions relating to their employment status, residential stability, 
social support, and interpersonal conflict. Additionally, their involvement in drug subculture, 
specifically the number of meth users they reside with and associate with is also gathered. 
The scores of each question are added together, with a higher score representing a greater 
level of dysfunction (Darke et al., 1991). 
(b)The timeline follow back (TLFB) is a self-reported quantitative estimate of the 
frequency of drug use within the previous three months of the interview (Sobell et al., 1996).  
(c)Severity of cravings are assessed via the visual analogue scale (VAS). The VAS is 
a continuous scale utilising a 100mm fixed horizontal line, ranging from a score of zero (no 
cravings) to a score of 10 (most cravings ever experienced). It contains only one item, which 
asks the participant to indicate the severity of their cravings on the horizontal line (Jensen et 
al., 2003).  
(d)The severity of dependence scale (SDS) is a self-administered questionnaire 
containing five questions which explores certain behavioural elements of drug dependence, 
such as the amount, frequency, duration of use, and the amount of time associating with other 
users. The SDS utilises a 4-point Likert scale, which ranges from 0 (never/almost never) to 3 
(always/nearly always). For methamphetamine, a score of four or more indicates drug 






(e)The World Health Organisation Quality of Life Scale (WHOQoL) is a self-reported 
measure of the individual’s perception of their overall quality of life in the previous four 
weeks. It consists of four domains, including physical health, psychological wellbeing, social 
relationships and environment. There are twenty-six items altogether, with one item asking a 
question to each of the domain’s facets. Physical health contains the facets: activities of daily 
living, dependence on medicinal substances and medical aids, energy and fatigue, mobility, 
pain and discomfort, sleep and rest, and work Capacity. Psychological wellbeing consists of: 
bodily image and appearance, negative feelings, positive feelings, self-esteem 
spirituality/religion/personal beliefs, and thinking, learning, memory and concentration. 
Social relationships is made up of personal relationships, social support, and sexual activity. 
Environment entails the sub-facets: financial resources, freedom, physical safety and security, 
health and social care: accessibility and quality, home environment, opportunities for 
acquiring new information and skills, participation in and opportunities for recreation/leisure 
activities, physical environment (pollution/noise/traffic/climate) and transport. The 
questionnaire utilises a five-point Likert scale, where a score of one represents “very 
poor/very dissatisfied/not at all or never” and five indicates “always/very satisfied/very 
well/completely/extremely/very good or an extreme amount.” All facets’ scores within each 
domain are added together to calculate an overall domain score, which is then multiplied by 
four to obtain a value out of one hundred (Skevington et al., 2004).  
(f)The Depression, Anxiety and Stress Scale (DASS- 21) assesses the severity of the 
individual’s reported depression, anxiety and stress. It contains twenty-one items which are 
measured on a four-point Likert scale, ranging from zero (did not apply to me at all) to three 
(applied to me very much, or most of the time). For the measure of depression, 0 to 4 
indicates a normal range, 5 to 6 is mild, 7 to 10 is moderate, 11 to 13 is severe and 14+ is 






range, 4 to 5 being mild, 6 to 7 as moderate, 8 to 9 being severe, and 10+ being extremely 
severe. Finally, for stress, a score of 0 to 7 is in the normal range, 8 to 9 is mild, 10 to 12 is 
moderate, 13 to 16 is severe and 17+ is considered extremely severe stress (Lovibond & 
Lovibond,1995).  
(g)The Kessler-10 (K10) reports the individuals’ levels of psychological stress within 
the previous twenty-eight days. The self-administered questionnaire contains ten items across 
a five-point Likert scale ranging from one “none of the time” to five “all of the time”. A score 
between ten and twenty points indicates a healthy range, a score between twenty and twenty-
four suggests a mild level of stress, moderate stress is represented by a score of twenty-five to 
twenty-nine, and a score of thirty to fifty indicates severe mental stress (Kessler et al., 2003) 
2.3 Procedure 
Longitudinal data were available in that the outpatients were assessed at two different 
time points, the first being prior to program commencement and then 16 weeks later, upon 
finishing the program. After initially contacting PsychMed, outpatients determined their 
eligibility for the program by completing the World Health Organisation Alcohol, Smoking 
and Substance Involvement Screening Test (ASSIST), which screened for risky and 
problematic substance use. Participants were assigned to either a “mild,” “moderate” or 
“severe” group. If they were considered “severely” addicted to meth, then they were accepted 
into the program. All outpatients were required to attend an induction session and had 
provided their informed consent by signing a program contract. They were then debriefed on 
the program’s rules and were introduced to the psychologists and the lived experience 
mentor. At both the initial and post treatment assessments, the TLFB; OTI for 
methamphetamine use and social functioning; WHOQoL overall raw score, physical health, 
psychological, social relationships, and environment; K10; DASS-21; SDS and VAS scores 






2.4 Analytical approach 
A new variable which categorised methamphetamine and hallucinogen combinations 
was also created. 0 = no hallucinogen use, that is, those who purely use methamphetamine; 1 
= methamphetamine and LSD use; 2 = methamphetamine and psilocybin use; 3 = 
methamphetamine, LSD and psilocybin use; and 4 = methamphetamine and MDMA use. An 
additional variable was created, which categorised participants into either a 
methamphetamine only group or a methamphetamine and hallucinogen group, which 
combined all use of any hallucinogens together. For the reliable change indices (RCI) test, the 
difference between the post Matrix program mean score and the pre Matrix program mean 
scores for each significant measure were calculated, and made into new separate variables.  
Chi squared tests were used to test whether gender, ATSI status, and age were 
associated with abstaining or engaging in hallucinogen use. An ANOVA was used to observe 
whether the differences in each measure’s mean scores between non hallucinogen, LSD, 
psilocybin and MDMA users were significant. To test whether the differences in mean scores 
between 16 to 25 year olds, 25 to 35 year olds, 35 to 45 year olds, and 45 to 67 year olds 
were significant, an ANOVA was also conducted. T-Tests were utilised to compare the 
significance in the differences in mean scores between hallucinogen and non hallucinogen 
users, and in males and females. For the final analyses, a mixed ANOVA was conducted to 
test the significance of the differences in mean scores between non hallucinogen and 
hallucinogen users at intake into Matrix program and post Matrix program completion. 
Additionally, this test identified the measures that displayed time as a significant main effect. 
Finally, a reliable change indices test was run to determine each measure’s exact score that 
represented a reliable change across the two time points. Then, the number of cases that 
displayed an improvement, deterioration and no change in scores could be determined. Chi 






using hallucinogens were associated with the improvement or deterioration in mean scores 





























Chapter 3. Results 
 
3.1 Analysis of baseline Scores based on hallucinogen usage 
Table 2. 




































Male 145 249 11.45*** 
Female 123 121  
    
Aboriginal/Torres Strait Islander    
Yes 12 22 .303 
No  166 248  
    
Age    
16-25 18  29 .481 
25-35 99 131  
35-45 97 135  







Comparison of scores at baseline between different substance groups 
___________________________________________________________________________
___________________________________________________________________________ 


























(n = 28) 
M (SD) 
LSD & Psilocybin 
 
















Depression 15.8(11.4) 16.9(11.7) 20.7(9.6) 18.6(11.1) 16.0(12.1) 1.818 .012 
Anxiety 13.3 (9.9) 14.1(9.9) 20.0(7.7) 14.1(9.2) 13.8(10.2) 2.548* .017 
Stress 17.1(10.6) 18.2(10.5) 21.5(8.9) 19.0(9.5) 18.3(10.5) 1.424 .010 
        
WHOQoL        
Overall Raw Score 6.1(2.4) 5.8(1.8) 5.4(1.3) 5.6(1.8) 9.2(15.1) 5.437*** .035 
Physical Health  43.3(25.1) 41.0(22.6) 40.6(15.3) 38.6(21.9) 38.3(20.5) .914 .006 
Psychological 35.7(22.0) 35.9(21.6) 34.4(18.2) 35.8(21.4) 32.8(20.0) .148 .001 
Social Relationships 38.9(29.1) 39.5(25.7) 35.6(19.9) 38.4(25.9) 39.1(23.5) .123 .001 
Environment 48.0(24.4) 49.3(22.8) 49.4(19.3) 47.1(23.9) 48.5(18.2) .186 .001 
        
K-10 27.2(9.5) 27.1(9.4) 31.6(7.3) 28.4(9.0) 26.6(9.6) 1.772 .011 
        
OTI           
Methamphetamine 1.3(2.2) 2.0(6.2) 1.3(1.9) 2.0(3.3) 1.1(1.9) 1.147 .007 
Social Functioning 17.9(7.2) 18.1(7.5) 18.8(5.6) 18.9(7.1) 15.0(6.5) 1.684 .011  
        
SDS 8.2(3.7) 8.8(7.5) 8.8(3.7) 8.7(4.0) 7.7(4.5) .509 .003 
        
VAS 5.7(3.0) 6.6(7.2) 6.5(2.9) 6.6(2.6) 6.3(3.5) 1.219 .008 
        







Comparison of scores at baseline between non-hallucinogen use and hallucinogen-use 
___________________________________________________________________________ 
___________________________________________________________________________ 
*p<.05 **p<. 01 *** p<.001 
Table 2 indicates the association between demographic characteristics and 
hallucinogen use. The results indicate that usage differed by gender, with significantly more 
males reporting having used LSD, psilocybin and MDMA than women. Women were more 
likely to report not using hallucinogens, predominantly only using meth. Further comparisons 
of baseline scores for psychological measures are provided in Table 3. As indicated, LSD, 
psilocybin and MDMA users obtained higher scores for the DASS-21 Anxiety subscale, but 
no differences were observed for the other subscales. No significant differences were 







(n = 268) 
M (SD) 
 
LSD, Psilocybin, MDMA 
 










DASS-21      
Depression 15.8(11.4) 17.6(11.4) 1.896 .158 
Anxiety 13.3 (10.0) 14.5(9.7) 1.345 .122 
Stress 17.2(10.7) 18.7(10.1) 1.766 .144 
     
WHOQoL     
Overall Raw Score 6.1(2.4) 6.0(4.5) .415 .022 
Physical Health*** 43.4(25.1) 40.1(21.7) 1.741 .141 
Psychological 35.7(22.1) 35.5(21.1) .094 .009 
Social Relationships*** 38.8(29.1) 38.9(25.1) 0.26 .004 
Environment* 48.1(24.5) 48.6(22.5) .262 .021 
     
K-10 27.2(9.5) 27.8(9.2) .741 .064 
     
OTI        
Methamphetamine** 1.3(2.2) 1.9(5.0) 1.729 .170 
Social Functioning 17.9(7.2) 18.2(7.2) .372 .042 
     
SDS 8.2(3.7) 8.7(6.2) 1.115 .101 
     
















found to be significantly higher in the MDMA group than in the other three groups. Further 
comparisons (Table 4) based on a binary classification of clients in users and non-users of 
hallucinogen users revealed no significant differences except for the VAS. Hallucinogen 
users had higher VAS or urges scores than non-users.  
3.2 Gender and age comparisons 
Table 5. 
Comparison of scores at baseline across gender 
________________________________________________________________ 
_______________________________________________________________ 



























DASS-21      
Depression 16.9(11.4) 17.8(12.0) 1.376 .077 
Anxiety 13.8(10.0) 15.0(10.2) 1.781 .119 
Stress 18.0(10.4) 19.1(10.7) 1.525 .104 
     
WHOQoL     
Overall Raw Score 6.3(5.4) 5.8(2.2) 1.417 .132 
Physical Health  43.0(22.9) 42.3(23.7) .506 .030 
Psychological 37.3(21.3) 34.1(21.2) 2.297* .151 
Social Relationships 37.8(26.6) 38.6(27.6) .465 .030 
Environment 48.8(22.6) 47.9(23.7) .621 .039 
     
K-10 27.6(8.9) 28.9(9.6) 2.151* .141 
     
OTI     
Methamphetamine 1.8(3.1) 1.8(5.0) .021 .001 
Social Functioning 17.2(7.1) 19.5(7.4) 5.123*** .317 
     
SDS 8.2(3.6) 8.6(6.1) 1.464 .082 
     
VAS 6.1(2.9) 6.3(5.4) .726 .048 
     











*p<.05 **p<. 01 *** p<.001 
It was also important to examine whether baseline scores differed by gender (Table 
5). These comparisons indicated that women had poorer psychological quality of life scores, 
higher K10 scores, but better social functioning scores. All other comparisons were non-
significant. Age differences are presented in Table 6 and showed that the youngest age group, 






16 – 25 
 
(n = 90) 
M (SD) 
25 - 35 
 
(n = 409) 
M (SD) 
35 - 45 
 
(n = 425) 
M (SD) 
 
45 - 67 
 












Depression 19.9(11.8) 16.4(11.4) 17.3(11.7) 18.1(11.6) 2.006 .007 
Anxiety 18.2(9.0) 14.1(10.6) 13.6(9.8) 14.1(9.8) 3.748* .013 
Stress 21.7(9.7) 18.2(10.8) 18.4(10.5) 17.5(9.9) 2.476 .008 
       
WHOQoL       
Overall Raw Score 7.3(11.9) 5.9(1.7) 6.2(4.8) 5.5(1.9) 2.625* .009 
Physical Health  42.0(21.6) 42.4(23.2) 43.5(23.7) 40.0(22.6) .902 .003 
Psychological 33(19.3) 35.8(20.5) 36.8(22.5) 35.1(21.7) .821 .003 
Social Relationships 37.9(27.3) 40.0(26.6) 36.8(22.5) 36.9(27.3) .842 .003 
Environment 46.1(21.1) 49.0(23.0) 48.6(22.9) 47.0(24.1) .542 .002 
       
K-10 30.0(9.8) 27.8(8.9) 28.1(9.4) 27.9(9.1) 1.446 .004 
       
OTI             
Methamphetamine 2.9(4.8) 2.0(5.2) 1.5(2.5) 1.5(2.6) 3.418* .010 
Social Functioning 18.4(7.1) 18.5(7.3) 17.6(7.3) 17.6(7.4) 1.184 .003 
       
SDS 8.0(4.2) 8.4(3.9) 8.4(5.8) 8.3(3.8) .201 .001 
       
VAS 6.0(3.2) 6.2(3.0) 6.2(5.5) 6.3(3.0) .143 .000 
       






methamphetamine OTI and highest on DASS anxiety. All other differences were non-
significant.  
3.3. Post treatment outcomes 
Table 7.  
Mixed ANOVA comparing scores pre and post treatment 
___________________________________________________________________________
___________________________________________________________________________ 
*p<.05 **p< .01 ***p< .001 
A 2 Group x 2 Time mixed ANOVA was conducted to examine group differences in 
outcomes across time (Table 7). Table 7 indicates a significant Time main effect for TLFB 
scores had a highly significant main affect for time. Other significant main effects for Time 
included the DASS-21 for anxiety, the WHOQoL psychological scores and environment 



































    F 
DASS-21         
Depression 10.8(9.3) 15.1(11.5) 6.1(7.1) 9.2(8.5) 1.856 5.261* .627 .242 
Anxiety 10.6(10.2) 12.4(10.2) 5.2(7.2) 7.7(7.9) 5.232* 1.419 .652 .193 
Stress 13.8(10.6) 16.5(10.8) 8.4(9.4) 10.8(8.5) 2.069 2.168 .192 .033 
         
WHOQoL         
Overall Raw Score 7.2(4.0) 6.1(1.5) 10.0(16.2) 6.9(1.6) .001 2.344 2.295 .547 
Physical Health 46.1(26.6) 36.3(20.9) 51.5(26.5) 47.0(27.5) 3.610 2.998 .518 .682 
Psychological 36.6(22.6) 31.1(19.5) 45.9(26.2) 39.3(24.1) 4.250* 2.482 .495 .129 
Social 
Relationships 
38.2(28.7) 31.4(25.3) 38.9(25.8) 40.0(30.6) 2.091 .366 .010 .460 
Environment 47.7(23.8) 43.2(21.8) 54.1(24.2) 51.2(28.5) 5.723* .784 .090 .006 
         
K-10 24.4(10.) 26.9(10.5) 19.4(8.6) 21.1(9.4) 5.276* 1.402 .627 .113 
         
OTI         
Methamphetamine 1.2(2.4) 2.9(9.9) .07(.25) .71(2.8) .363 3.142 2.954 .846 
Social Functioning 16.9(6.9) 17.3(7.6) 13.6(7.5) 14.3(6.6) 2.055 .657 3.639 .022 
         
SDS 7.1(3.7) 8.4(4.7) 2.3(3.6) 3.5(4.1) 5.715* 2.692 .814 .099 
         
VAS 5.1(3.4) 5.7(3.1) 3.2(3.3) 3.7(3.4) 4.423* .893 .145 .002 
         
TLFB 32.4(29.4) 33.3(31.7) 4.0(15.2) 4.4(9.2) 14.865
*** 






scores, the Kessler-10, the SDS and the VAS. All these results indicated that scores on these 
measures had improved over time. There was one significant Group main effect for DASS 
depression with the hallucinogen group found to have generally higher scores (note that this 
is a subsample of the larger sample for whom data was available at both time points). 
3.4 Reliable change indices  
Table 8. 




Reliable change indices (RCIs) were calculated to determine the percentage of cases 
for the important outcome measures that had experienced statistically reliable changes in 
scores (Table 8). Table 8 indicates that 27% of cases had reliable improvements in DASS 
Anxiety scores, 40% had reliable improvement in K10 scores, and over 40% reliable 




Measure n Required Difference Improvement Deterioration 
 
No Reliable Change 

















      
WHOQoL      
Psychological 151 +24 39 26 15 10 97 64 
Environment 151 +29 30 20 6 4 115 76 
      
K-10 186 -9 75 40 7 4 104 56 
      
SDS 179 -7 55 31 0 0 124 69 
      
VAS 178 -3 77 43 13 7 88 49 
      






Chapter 4. Discussion 
4.1 Overview of Results 
Analyses of the Matrix program data was undertaken to assert whether hallucinogen 
use is related to higher or lower levels of psychological, physical and social harm in people 
addicted to meth upon intake and completion of the program. As hypothesised, individuals 
who engaged in hallucinogen use had higher levels of harm than those who consumed meth 
only. This took the form of higher scores for the DASS depression and anxiety subscales as 
well as the VAS. A secondary aim of the study was to explore whether age and gender 
differences impact treatment outcomes in those participating in the Matrix program 
regardless of polysubstance use. Although women did not engage in as much polysubstance 
use as men, they reported poorer psychological quality of life scores, higher K10 scores and, 
unexpectedly, better social functioning scores. Moreover, when comparing different age 
groups, the youngest age group (sixteen to twenty- five year olds) presented the highest raw 
overall quality of life scores as well as highest methamphetamine OTI and DASS anxiety 
scores. Finally, the study provided insights into the outcomes for the program. These analyses 
showed that drug rehabilitation should tailor their programs to these vulnerable populations in 
order to improve treatment outcomes. 
At baseline, the scores for the DASS-21 anxiety subscale where higher for LSD, 
psilocybin and MDMA users than meth only users. Although there is emerging research that 
hallucinogens may be beneficial for treating addiction and anxiety, they can also induce “bad 
trips” (Gashi et al., 2021). A “bad trip” is a negative psychedelic experience in which the user 
may experience distressing and frightening visual and/or auditory hallucinations, evoking 
severe paranoia, anxiety attacks, and psychosis (Van Amsterdan et al., 2011). Research has 
shown that individuals who use multiple drugs and have pre-existing mental illnesses are 






hallucinogens are relatively common, with a 2004 survey from the United Kingdom revealing 
that out of 174 psilocybin users, approximately one third experienced anxiety and one third 
experienced paranoia (Riley & Blackman, 2008). 
As a result, it can be speculated that Matrix program outpatients who also use 
hallucinogens would have an increased risk of experiencing a “bad trip” and the associated 
negative effects of hallucinogens. This may explain why Matrix outpatients who use 
hallucinogens have higher rates of anxiety than those who abstain from hallucinogens. 
Furthermore, the use of hallucinogens can sometimes exacerbate pre-existing mental 
illnesses, with anxiety disorders being the most prone, and can also elicit an earlier onset in 
mental illnesses which have not emerged yet (Nichols, 2016).  
It must be stressed that the therapeutic benefits of hallucinogens have primarily been 
demonstrated in clinical settings, where the dosage and purity of the hallucinogens have been 
monitored and controlled by scientists and health professionals (Krebs & Johansen, 2013). 
Due to the illegality of these substances, outpatients of the Matrix program only have access 
through the black market, where the manufacturing is unknown and the purity is unregulated. 
This is typically an issue for MDMA, as its pill form means adulterants such as amphetamine, 
methamphetamine, cocaine and ketamine can be discretely added by black market 
manufacturers to stretch the supply of the drug and maximise profit. With stimulants being 
the most common adulterants, the compounding effects of these with meth can severely 
increase anxiety, paranoia and psychosis (Saleemi et al., 2017). Furthermore, not moderating 
the dosage and frequency of using hallucinogens can also contribute to mental health issues 
and poorer outcomes. Research that is in favour of hallucinogen use emphasises that the 
greatest benefits are experienced when individuals micro-dose such substances (Anderson et 
al., 2019). However, for individuals who are addicted to meth, it is easy to abuse 






emerging evidence supporting the use of hallucinogens in treating mental illness, specific 
dosing and environmental factors are necessary to achieve positive outcomes and therefore 
use in the community by Matrix program users have shown to be negatively impacting 
treatment outcomes.  
Although all scores improved from baseline upon completion of the Matrix program, 
outpatients who use hallucinogens still obtained higher DASS depression scores than the 
remainder of the sample. Many individuals who engage in polysubstance use have a pre-
existing history of mental illness, specifically depression and can self-medicate with 
hallucinogens as a way to treat their symptoms (University of Queensland, 2021). Feelings of 
enlightenment and acceptance are often expected to be experienced by the individual after 
consuming hallucinogens. However, self-medication may elicit a paradoxical effect due to 
the drugs unpredictable nature and may result in adverse effects on the person’s mental 
health. For example, an individual who experiences depressive thoughts during a psychedelic 
trip may become convinced that these thoughts are true about themselves, leading to a self-
fulfilling  prophecy (Nesvag et al., 2015). Therefore, it is speculated that individuals 
consuming hallucinogens may have bad experiences which results in worse depressive 
symptoms compared to meth only people. Moreover, it can be speculated that for individuals 
taking  MDMA, a drug which depletes serotonin, the comedown can often result in 
depressive symptoms that may last for up to a week after use (Mustafa et al., 2020). 
Hallucinogen persisting perception disorder was added to the DSM- 5 in 2012 and consists of 
the re-occurrence of unpleasant visual and auditory sensations related to negative trips 
(Martinotti et al., 2018). Although the acute effects of a bad trip may have subsided, 
individuals may experience feelings of depression even months after consuming 
hallucinogens. Evidently, outpatients engaging in polysubstance use have higher post 







The higher VAS craving scores among hallucinogen users was also expected, as these 
outpatients were detoxing from multiple substances. Although hallucinogens are not 
physically addictive, there is still evidence that they may be psychologically addictive 
(Nichols, 2016). Like meth, hallucinogens, especially MDMA also cause an increase in 
serotonin when consumed, also resulting in a significant depletion of it when the effects 
eventually subside. This causes a strong desire and craving to repeat the dose in order to 
replenish serotonin levels (Kish et al., 2017). If these effects are compounded with meth use, 
this means that there is an even greater “crash” and depletion of serotonin, which increases 
the severity of cravings for multiple drugs, rather than just a single drug (Mustafa et al., 
2020). The risk of developing a tolerance, even after only consuming a few doses, is also 
quite high for hallucinogen use. Each time, users may need to increase their dosage to obtain 
the desirable effects, causing users to develop a greater craving for certain hallucinogens 
(Nichols, 2016). 
Although men had higher levels of hallucinogen use, women experienced higher 
levels of anxiety on the K10 scale and poorer psychological quality of life scores. This is 
consistent with the literature which consistently indicates that women possess a higher 
prevalence of generalised anxiety disorder, panic disorder, social anxiety disorder, and 
posttraumatic stress disorder (Vesga-Lopez et al. 2008). Women also have been shown to 
have a higher risk of anxiety symptoms during meth detox and withdrawal (Su et al., 2017). 
Female meth users were also associated with having a greater psychological burden, greater 
childhood emotional and sexual trauma, and were more prone to emotional-coping strategies 
(Simpson et al., 2016). It has also been found that depression and depression-like symptoms 






Furthermore, women report self-medicating with meth to escape emotional problems and 
improve their mood more frequently than men (Hser et al., 2005; Semple et al., 2004).  
Despite depression and anxiety being apparent comorbidities, women reported better 
social relationship quality of life scores than men. It was expected that women would have 
lower social relationships and support, as unwanted pregnancies and single parenting are 
common among female meth users (Dyba et al., 2019). Female meth users are more likely to 
have children younger than eighteen years old, have less emotional support, and higher 
parental role strain as a result of carrying the burden of raising their children.  Similarly, 
meth-using mothers are more likely to face social stigma and criticism due to traditional 
societal expectations of them being more nurturing and the primary caregiver (Semple et al., 
2011). Single mothers who use are also vulnerable to losing custody of their children. Other 
research (e.g., Semple et al., 2009) indicates that conflict with other family members in 
relation to the care and protection of underage children is a significant contributing factor to 
female meth users possessing lower quality personal relationships.  However, this was not 
consistently observed in this study in that female meth-users reported positive sexual 
relationships. Research has found that women experience increased desire, pleasure, 
disinhibition and feelings of power and agency while engaging in sexual acts under the 
influence of methamphetamine (Kittirattanapaiboon et al., 2017).  
The youngest cohort of polysubstance users had the highest raw overall quality of life 
score. Younger meth users may perceive their overall quality of life to be better for a variety 
of reasons. Younger people have less physical health-related comorbidities. Additionally, 
younger users are more likely to have been using meth for a shorter period of time, meaning 
the long-term negative effects may have not yet emerged or may be less pronounced than in 
older users (Russell et al., 2008). Younger meth users also have the financial security of 






likely to be homeless than older users (Fast et al., 2014). Younger people also have more 
social protective factors, having larger groups and numbers of friends, and reportedly being 
significantly less lonely than older people (Bungay et al., 2009). Additionally, younger users 
are less likely to have the added pressures and responsibilities of having their own children to 
look after (Asante & Lentoor, 2017).  
Despite having the highest raw overall quality of life score, the cohort of sixteen to 
twenty-five-year-olds scored higher on the DASS anxiety than those aged between twenty-
five and sixty-seven years of age. This is supported by the literature, which demonstrates that 
Australians aged between sixteen and twenty-four years old have the highest prevalence of 
mental illness than any other age group, showing a decrease with age. Approximately one in 
five Australians aged between fifteen and nineteen years of age have a mental illness, 
compared to only one in twenty for Australians aged seventy-five to eighty-five years. 
Anxiety disorders are also the most prevalent among the fifteen- to nineteen-year-old cohort 
(Ivancic et al., 2014). It is impossible to determine the exact reasons why younger me 
Australians who use meth are more anxious than older meth users, but one possible 
explanation is the prevalence of peer pressure. Peer pressure was identified as a strong 
motivator for young Australians trying meth for the first time (Kelly et al., 2013). It can be 
assumed that the pressure of fitting in for young and impressionable individuals would have 
higher levels of anxiety. Social media use is also strongly associated with higher rates of 
anxiety in younger people (Barthorpe et al., 2020). It can be very misleading, often depicting 
only the most desirable and glamourous aspects of other people’s lives. This can make young 
people feel inadequate and inferior, often constantly comparing themselves to one another, 
and feeling pressure to gain more likes and followers (Hollis et al., 2020). 
The study’s findings that Matrix program clients aged between sixteen and twenty-






expected. The literature consistently reports that meth use in Australia is highest amongst 
teenagers and individuals in their twenties (Australian Institute of Health and Welfare, 2021b; 
Degenhart et al., 2016). Although there is no specific evidence on why this may be the case, 
there are some trends in meth usage that are more commonly associated with younger people. 
It is widely reported that meth is often used socially while partying at nightclubs and at house 
parties, with frequent clubbing being correlated with higher meth use (Green et al., 2016; The 
Australian Government Department of Health, 2008). Specifically, social users are attracted 
to its effects of increased confidence and assertiveness in social interactions, and increased 
energy, which allows them to dance for hours at a time and party for days at a time 
(Degenhart et al., 2009). It can be assumed that younger meth users, would be more inclined 
to use meth for dancing and excessive partying, making it more popular among this cohort 
than older among older users. 
Meth is also reportedly used among high school and university students to increase 
alertness, concentration and productivity while studying (Fast et al., 2014). In particular, 
students report that meth’s energy increasing effects allows them to study for hours at a time 
and until the early hours of the morning (Peterson et al., 2013). In an American study of 
college students, existing meth users were prone to increasing their meth use in their final 
years of college to help them cope with the increased stress associated with their final exams. 
Additionally, the reduction in fatigue, increased reading comprehension and interest, and 
improved memory were other benefits to using meth for studying (DeSantis et al., 2010). 
Finally, younger people may be more likely to use meth due to its affordability in comparison 
to other stimulants, such as cocaine and amphetamines. Since the Covid-19 pandemic, in 
Australia, a gram of meth costs $250 on average, whereas a gram of cocaine costs $450 
(Rawsthorne, 2020). The affordability of meth means that it would be considerably more 







There were several limitations to this study that prevented the generalisation of the 
results. First, the vulnerability of the cohort and the high level of commitment needed to 
complete the Matrix program meant that the program was prone to high levels of attrition. As 
a result, the follow-up data was biased and positive outcomes may have been 
overrepresented, containing outcome scores only from motivated meth users. Another 
limitation was that the number of times outpatients had attempted treatment and rehabilitation 
in the past was not gathered. Being aware of this would help Matrix program staff predict 
which outpatients are most at risk of dropping out of the program, allowing them to provide 
extra support and guidance in areas that have made outpatients susceptible to relapse.  
Second, many important confounding factors that influence the amount of harm 
experienced by outpatients were not reported or taken into consideration. For example, 
outpatients’ preferred method of consumption was not indicated. The literature widely reports 
that the smoking of methamphetamine hydrochloride, as opposed to injecting or snorting 
powder methamphetamine, significantly increases the level of psychological and physical 
harm to the user, as well as the interaction it has with secondary substances (Kalaitzopoulos 
et al., 2018). Undoubtedly, this distinction would influence the level of comorbidity and type 
of treatment outpatients require. Similarly, many comorbidities were also not reported, such 
as pre-existing medical and psychological diagnoses. Being aware of such information would 
allow medical professionals to determine how certain confounding factors influence 
polysubstance use, and which populations of meth users are most vulnerable.   
A third issue is that most of the measures are self-report based which increases the 
likelihood of social-desirability bias. Due to concerns about privacy, people may have under-
reported their level of usage or the range of problems being experienced. Finally, there may 






Islander people is known to be three times higher than the rest of the Australian population 
(Australian Institute of Health and Welfare, 2017). However, only 3.4% of the 1159 Matrix 
clients identified as Aboriginal or Torres Strait Islander, suggesting that treatment 
accessibility may be an issue for this population. To improve this, mobile treatment services 
that visit rural Indigenous communities should be more readily available to provide education 
about the negative effects of meth addiction, and where to access treatment. Finally, another 
important comorbidity that was not investigated was the number of times outpatients had 
previously relapsed. This is an important detail because poorer mental health and social 
support is associated higher relapse rates (Brecht & Herbeck, 2014).  
4.3 Implications & Future Directions 
Research suggests that polysubstance use is associated with greater and more severe 
comorbidities than singular drug use. Consequently, individuals who engage in polysubstance 
use need to receive more attention and receive treatment that is tailored to the combination of 
drugs they consume. An individualised approach is required to treat individuals who engage 
in polysubstance use. This means training clinicians to provide personalised recovery plans to 
address the issues that are related to the myriad of substances the individual may be using, 
and also exploring the patterns of their drug use combinations and the reasons in engaging in 
polysubstance use (Black et al., 2017). It is often that multiple drugs are used for their unique 
differences in effects. For instance, meth may be used to increase productivity at work or 
while studying, whereas MDMA may be used socially in a nightclub setting (Radfar & 
Rawson, 2014; Degenhart et al., 2009). Treating an individual’s primary substance and 
neglecting the treatment of secondary substances will make them more susceptible to relapse 
(Brecht & Herbeck, 2014) This is because they are still involved in the drug subculture 






how their polysubstance use is related to their primary drug use, and how this hinders 
treatment outcomes.  
Future research also needs to explore whether treating all substance abuse 
simultaneously is more effective than treating each substance abuse individually. The 
literature currently has only investigated how meth interacts with depressants, such as alcohol 
and opioids, and stimulants, such as cocaine. Future research should explore how 
hallucinogens interacts with meth, so clinicians can gain an in depth understanding of why 
hallucinogens are associated with lower treatment outcomes. An abstinence model, rather 
than a harm reduction model, needs to be encouraged during outpatient order to ensure 
positive treatment outcomes (Subbaraman & Witbrodt, 2014). For individuals who are prone 
to addiction, they may “swap out” their primary addiction for the secondary substances they 
are already consuming, which is why it is best to abstain from all substances entirely during 
recovery (Fernandez et al., 2020). This research will give outpatient drug rehabilitation 
programs the evidence to shift their focus onto addressing secondary substance use and how 
it interacts with primary addiction. Moreover, while there are acceptable levels of alcohol 
consumption, there are no acceptable levels of drug use, even if they are less harmful like 
hallucinogens. With consent granted from the government, rehabilitation programs for 
individuals addicted to methamphetamine can trial micro-dosing of hallucinogens to treat 
addiction. Many scientific trials have already been conducted in Australia, however, currently 
there have been no trials for hallucinogen use in treating meth addiction.  
4.4 Conclusion 
With meth’s severe detriment on the livelihood of individuals and its increasing 
burden on the public health system, it has been more important than ever to study the 
comorbidities that contribute to meth addiction. A common comorbidity among meth users is 






depressants and other stimulants, there is limited research on the combination of meth use 
and hallucinogen use. Therefore, this study addressed the gap in the literature by comparing 
outpatients in rehabilitation who are addicted to meth and consume LSD, psilocybin, and/or 
MDMA, with outpatients who only use meth. The study’s aims were to explore whether meth 
users who use hallucinogens experience worse physical, psychological and social harm than 
users who only use meth. Confirming the hypothesis, the results revealed that higher levels of 
harm were experienced by meth users who use hallucinogens than individuals who only use 
meth. Specifically, meth and hallucinogen users obtained higher scores for the DASS 
depression and anxiety subscales, and higher VAS scores. Gender and age differences were 
also investigated in meth outpatients, with women obtaining poorer psychological quality of 
life scores, higher K10 scores and, unexpectedly, better social functioning scores. 
Furthermore, outpatients aged between sixteen and twenty-five years old achieved the highest 
raw overall quality of life scores as well as highest methamphetamine OTI and DASS anxiety 
scores. These findings will aid public health initiatives and rehabilitation programs in 
identifying which populations are most vulnerable, allowing their services to be better 
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